Vir Biotech 'Aggressively Working' On Potential Wuhan Coronavirus Treatment
Vir late Wednesday said it's working rapidly to determine whether its previously identified anti-coronavirus monoclonal antibodies, or mAbs, possess the potential to bind and neutralize the Wuhan coronavirus, aka 2019-nCoV.
These mAbs, according to the company, were discovered using its antibody platform from the survivors of an infection. Some of these may have the potential to treat and prevent Wuhan coronavirus.